China has blocked GSK from participating in its national bulk-buy drug procurement program from Oct. 31 until April 29, 2024 over quality problems with a prostate drug, the British drugmaker said on Monday.
https://www.pharmalive.com/wp-content/uploads/2022/10/ReutersGSK10-27-2022.webp7701200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-31 09:45:072022-10-31 10:47:12China bars GSK from bulk-buy drug program for 18 months
